A combination of 2D similarity search, pharmacophore, and molecular docking techniques for the identification of vascular endothelial growth factor receptor-2 inhibitors

Anti-Cancer Drugs

Volumn 26, Issue 4, 2015, Pages 399-409

  Ai, Guanhua ^a   Tian, Caiping ^a   Deng, Dawei ^a   Fida, Guissi ^a   Chen, Haiyan ^a   Ding, Li ^a   Ma, Yuxiang ^a   Gu, Yueqing ^a  

^a China Pharmaceutical University   (China)

Author keywords

2D similarity search; molecular docking; pharmacophore modeling; vascular endothelial growth factor receptor 2 inhibitors

Indexed keywords

UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 INHIBITOR; ANGIOGENESIS INHIBITOR;

ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL PROLIFERATION; CRYSTAL STRUCTURE; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG SCREENING; GENETIC ALGORITHM; HUMAN; HUMAN CELL; HYDROGEN BOND; LIGAND BINDING; MOLECULAR DOCKING; PHARMACOPHORE; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY; ANTAGONISTS AND INHIBITORS; CHEMICAL DATABASE; CHEMISTRY; DRUG DESIGN; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; CELL LINE, TUMOR; DATABASES, CHEMICAL; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR DOCKING SIMULATION; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84925491288     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000199     Document Type: Article

References (32)

1. Eckert H, Bajorath J. Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches. Drug Discov Today 2007; 12 (5-6):225-233.
2. Raymond JW, Willett P. Effectiveness of graph-based and fingerprint-based similarity measures for virtual screening of 2D chemical structure databases. J Comput Aided Mol Des 2002; 16:59-71.
3. Wilson GL, Lill MA. Integrating structure-based and ligand-based approaches for computational drug design. Future Med Chem 2011; 3:735-750.
4. Lucas S, Heim R, Negri M, Antes I, Ries C, Schewe KE, et al. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem 2008; 51:6138-6149.
5. Drwal MN, Griffith R. Combination of ligand- and structure-based methods in virtual screening. Drug Discov Today Technol 2013; 10:e395-e401.
6. Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, et al. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res 2003; 63:7301-7309.
7. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368-4380.
8. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004; 10 (Pt 2):6388S-6392S.
9. Podar K, Catley LP, Tai YT, Shringarpure R, Carvalho P, Hayashi T, et al. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood 2004; 103:3474-3479.
10. Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006; 11:753-764.
11. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11:83-95.
12. Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008; 14:6146-6153.
13. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008; 26:4708-4713.
14. Annunziata CM, Walker AJ, Minasian L, Yu M, Kotz H, Wood BJ, et al. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res 2010; 16:664-672.
15. Irwin JJ, Shoichet BK. Zinc - a free database of commercially available compounds for virtual screening. J Chem Inf Model 2005; 45:177-182.
16. Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: a free tool to discover chemistry for biology. J Chem Inf Model 2012; 52:1757-1768.
17. Bender A, Glen RC. Molecular similarity: a key technique in molecular informatics. Org Biomol Chem 2004; 2:3204-3218.
18. Kuriyama I, Nakajima Y, Nishida H, Konishi T, Takeuchi T, Sugawara F, et al. Inhibitory effects of low molecular weight polyphenolics from Inonotus obliquus on human DNA topoisomerase activity and cancer cell proliferation. Mol Med Rep 2013; 8:535-542.
19. Wu F, Xu T, He G, Ouyang L, Han B, Peng C, et al. Discovery of novel focal adhesion kinase inhibitors using a hybrid protocol of virtual screening approach based on multicomplex-based pharmacophore and molecular docking. Int J Mol Sci 2012; 13:15668-15678.
20. Mizushina Y, Shiomi K, Kuriyama I, Takahashi Y, Yoshida H. Inhibitory effects of a major soy isoflavone, genistein, on human DNA topoisomerase II activity and cancer cell proliferation. Int J Oncol 2013; 43:1117-1124.
21. Dehury B, Sahu M, Patra MC, Sarma K, Sahu J, Sen P, et al. Insights into the structure-function relationship of disease resistance protein HCTR in maize (Zea mays L.): a computational structural biology approach. J Mol Graph Model 2013; 45:50-64.
22. Petrie M, Lynch KL, Ekins S, Chang JS, Goetz RJ, Wu AH, Krasowski MD. Cross-reactivity studies and predictive modeling of 'Bath Salts' and other amphetamine-type stimulants with amphetamine screening immunoassays. Clin Toxicol (Phila) 2013; 51:83-91.
23. Vasiliou V, Sandoval M, Backos DS, Jackson BC, Chen Y, Reigan P, et al. ALDH16A1 is a novel non-catalytic enzyme that may be involved in the etiology of gout via protein-protein interactions with HPRT1. Chem Biol Interact 2013; 202 (1-3) :22-31.
24. Zhu J, Wu CF, Li X, Wu GS, Xie S, Hu QN, et al. Synthesis, biological evaluation and molecular modeling of substituted 2-aminobenzimidazoles as novel inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem 2013; 21:4218-4224.
25. Mark A, Johnson G. Concepts and applications of molecular similarity. 1st ed. New York, NY, USA: Wiley-Interscience; 1990.
26. Willett P. Similarity-based virtual screening using 2D fingerprints. Drug Discov Today 2006; 11 (23-24):1046-1053.
27. Lu XY, Chen YD, You QD. 3D-QSAR studies of arylcarboxamides with inhibitory activity on InhA using pharmacophore-based alignment. Chem Biol Drug Des 2010; 75:195-203.
28. Chaudhaery SS, Roy KK, Saxena AK. Consensus superiority of the pharmacophore-based alignment, over maximum common substructure (MCS): 3D-QSAR studies on carbamates as acetylcholinesterase inhibitors. J Chem Inf Model 2009; 49:1590-1601.
29. He G, Qiu M, Li R, Ouyang L, Wu F, Song X, et al. Multicomplex-based pharmacophore-guided 3D-QSAR studies of N-substituted 2'-(aminoaryl) benzothiazoles as Aurora-A inhibitors. Chem Biol Drug Des 2012; 79:960-971.
30. Ugale VG, Patel HM, Surana SJ. Molecular modeling studies of quinoline derivatives as VEGFR-2 tyrosine kinase inhibitors using pharmacophore based 3D QSAR and docking approach. Arab J Chem 2013 doi: 10.1016/j.arabjc.2013.07.026.
31. Musumeci F, Radi M, Brullo C, Schenone S. Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. J Med Chem 2012; 55:10797-10822.
32. Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 2004; 1:337-341.